Markets
Alerts
F&O
MF
Reports
Screeners
Subscribe
Superstars
Portfolio
Watchlist
Insider Trades
Results
Data Downloader
Events Calendar
What's New
Explore
FAQs
Widgets
More
Search stocks
IND
USA
IND
IND
×
Close
IND
USA
Stocks
Futures & Options
Mutual Funds
News
Fundamentals
Reports
Corporate Actions
Alerts
Shareholding
Overview
Buy Sell Zone
F&O
Financials
News
All
News
Earnings Calls
Corporate Announcements
Research Reports
Reports
Technicals
Technicals
Share Price History
Delivery
Shareholding
Shareholding
Monthly MF Holdings
Bulk Block Deals
Insider Trading & SAST
Deals
Bulk Block Deals
Insider Trading & SAST
Corporate Actions
All
Dividend
Bonus
Split
Rights
Board Meetings
Alerts
About
Aurobindo Pharma Ltd.
NSE: AUROPHARMA
|
BSE: 524804
|
ISIN: INE406A01037
|
Industry: Pharmaceuticals
US FDA Observation
|
Mid-range Performer
1040.2000
-3.90
(
-0.37
%)
NSE
Sep 08, 2025
15:31 PM
Near 52W Low of ₹1010.00
Volume:
415.8K
Share on Facebook
Tweet
Share on LinkedIn
Share via Whatsapp
Aurobindo Pharma Ltd.
16 Aug 2022
US FDA Observation
1040.20
-0.37%
US grows, margins shrink
Accumulate:
Aurobindo Pharma Ltd.
by
ICICI Securities Limited
Target: 632
Target
ICICI Securities Limited
Aurobindo Pharma’s (Aurobindo) Q1FY23 performance was below our estimates on profitability front.
Promoters pledged 0.16% of shares in last quarter. Total pledge stands at 17.08% of promoter holdings
More from Aurobindo Pharma Ltd.
Recommended
IPOs this week: Seven upcoming listings, Urban Company plus ten new issues
|
08 Sep 2025, 05:30PM
Market closes higher, Ujjivan SFB plans to raise around Rs 2,000 crore via a QIP
Trendlyne Marketwatch |
08 Sep 2025, 03:59PM
A deal is called off, increasing the chance for Aurobindo Pharma to be debt free
|
15 Jul 2020